LONG MINI-FUTURE - NOVO-NORDISK B | Market Closed - Börse Stuttgart 01:15:12 21/05/2024 pm IST | ||
| 21.55 EUR | +0.70% |
|
| 1 month | +5.94% | ||
| 3 months | +8.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 21/24/21 | 21.55 | +0.70% |
| 17/24/17 | 21.4 | -0.42% |
| 16/24/16 | 21.49 | +0.28% |
| 15/24/15 | 21.43 | +0.19% |
| 14/24/14 | 21.39 | +0.42% |
Delayed Quote Börse Stuttgart
Last update May 21, 2024 at 01:15 pm IST
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VN8M1E |
| ISIN | DE000VN8M1E1 |
| Date issued | 03/04/2017 |
| Strike | 109.9 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.22 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.71 € |
|---|---|
| Lowest since issue | 0.23 € |
| Spread | 0.53 € |
| Spread % | 2.38% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
927.2
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.94%
- Stock Market
- Certificates
- Certificat
